source
- Actimed regains full rights to S-oxprenolol, ends $126 million Faraday licensing dealActimed Therapeutics announced it has reclaimed all worldwide rights to its experimental wasting disease drug S-oxprenolol, terminating the licensing agreement it had with Faraday Pharmaceuticals.…
- Vistagen's anxiety nasal spray fails to outperform placebo in phase 2 trialVistagen Therapeutics reported that its experimental nasal spray fasedienol did not show a statistically significant advantage over placebo in a phase 2 study of social anxiety disorder. The trial…